中华传染病杂志
中華傳染病雜誌
중화전염병잡지
CHINESE JOURNAL OF INFECTIOUS DISEASES
2011年
2期
108-112
,共5页
孙洪清%黄琴%王江蓉%张仁芳%张学祥%董婕%戴振声%蔡卫平%卢洪洲
孫洪清%黃琴%王江蓉%張仁芳%張學祥%董婕%戴振聲%蔡衛平%盧洪洲
손홍청%황금%왕강용%장인방%장학상%동첩%대진성%채위평%로홍주
逆转录酶抑制剂%HIV感染%肝炎,丙型%抗逆转录病毒治疗,高效
逆轉錄酶抑製劑%HIV感染%肝炎,丙型%抗逆轉錄病毒治療,高效
역전록매억제제%HIV감염%간염,병형%항역전록병독치료,고효
Reverse transcriptase inhibitors%HIV infections%Hepatitis C%Antiretroviral therapy,highly active
目的 评价以依非韦仑为主的方案治疗HIV/HCV合并感染患者的安全性和有效性.方法 以依非韦仑为主的方案治疗53例HIV/HCV合并感染患者7年,观察CD4+T淋巴细胞计数、HIV RNA、肝功能、肝纤维化指标、血脂、血糖、血尿酸、血常规的变化.治疗前、后均数的比较采用t检验.结果 53例患者治疗前、后HIV RNA分别为(4.56±0.88)lg拷贝/mL和(1.70±1.10)lg拷贝/mL(t=14.781,P＜0.01);CD4+T淋巴细胞分别为(188.37±151.14)×106/L和(445.18±314.25)×106/L(t=5.362,P＜0.01);ALT分别为(36.6±16.3)和(57.2±9.9)U/L(t=7.864,P＜0.01);甘胆酸(CG)分别为(444.22±476.74)和(556.88±733.05)mg/L(t=0.938,P＜0.05);ⅣC分别为(45.13±8.25)和(47.88±4.51)ng/mL(t=2.129,P＜0.05);三酰甘油分别为(1.57±0.65)和(2.51±1.29)mmol/L(t=4.737,P＜0.01);血尿酸分别为(298.5±48.2)和(495.1±89.4)mmo1/L(t=14.092,P＜0.01).结论 以依非韦仑为主的方案治疗HIV/HCV合并感染患者是有效的,但可引起肝脏功能损害和代谢异常.
目的 評價以依非韋崙為主的方案治療HIV/HCV閤併感染患者的安全性和有效性.方法 以依非韋崙為主的方案治療53例HIV/HCV閤併感染患者7年,觀察CD4+T淋巴細胞計數、HIV RNA、肝功能、肝纖維化指標、血脂、血糖、血尿痠、血常規的變化.治療前、後均數的比較採用t檢驗.結果 53例患者治療前、後HIV RNA分彆為(4.56±0.88)lg拷貝/mL和(1.70±1.10)lg拷貝/mL(t=14.781,P＜0.01);CD4+T淋巴細胞分彆為(188.37±151.14)×106/L和(445.18±314.25)×106/L(t=5.362,P＜0.01);ALT分彆為(36.6±16.3)和(57.2±9.9)U/L(t=7.864,P＜0.01);甘膽痠(CG)分彆為(444.22±476.74)和(556.88±733.05)mg/L(t=0.938,P＜0.05);ⅣC分彆為(45.13±8.25)和(47.88±4.51)ng/mL(t=2.129,P＜0.05);三酰甘油分彆為(1.57±0.65)和(2.51±1.29)mmol/L(t=4.737,P＜0.01);血尿痠分彆為(298.5±48.2)和(495.1±89.4)mmo1/L(t=14.092,P＜0.01).結論 以依非韋崙為主的方案治療HIV/HCV閤併感染患者是有效的,但可引起肝髒功能損害和代謝異常.
목적 평개이의비위륜위주적방안치료HIV/HCV합병감염환자적안전성화유효성.방법 이의비위륜위주적방안치료53례HIV/HCV합병감염환자7년,관찰CD4+T림파세포계수、HIV RNA、간공능、간섬유화지표、혈지、혈당、혈뇨산、혈상규적변화.치료전、후균수적비교채용t검험.결과 53례환자치료전、후HIV RNA분별위(4.56±0.88)lg고패/mL화(1.70±1.10)lg고패/mL(t=14.781,P＜0.01);CD4+T림파세포분별위(188.37±151.14)×106/L화(445.18±314.25)×106/L(t=5.362,P＜0.01);ALT분별위(36.6±16.3)화(57.2±9.9)U/L(t=7.864,P＜0.01);감담산(CG)분별위(444.22±476.74)화(556.88±733.05)mg/L(t=0.938,P＜0.05);ⅣC분별위(45.13±8.25)화(47.88±4.51)ng/mL(t=2.129,P＜0.05);삼선감유분별위(1.57±0.65)화(2.51±1.29)mmol/L(t=4.737,P＜0.01);혈뇨산분별위(298.5±48.2)화(495.1±89.4)mmo1/L(t=14.092,P＜0.01).결론 이의비위륜위주적방안치료HIV/HCV합병감염환자시유효적,단가인기간장공능손해화대사이상.
Objective To evaluate the efficacy and safety of efavirenz-based therapy in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection. Methods Fiftythree HIV/HCV co-infected patients received efavirenz-based therapy were followed up for 7 years.The changes of CD4+ T lymphocyte count, HIV virus load, hepatic function, hepatic fibrosis index,blood lipid, blood glucose, blood uric acid and blood routine were observed. The comparison of means before and after treatment was performed by t-test. Results The HIV RNA levels at baseline and endpoint were (4. 56±0. 88) lg copy/mL and (1.70±1.10) lg copy/mL, respectively (t=14. 781, P＜0.01). The peripheral blood CD4+ T lymphocyte counts were ( 188.37±151.14)×106/L and (445.18±314.25)×106/L, respectively (t=5.362, P＜0.01).The alanine aminotransferase (ALT) levels were (36.6±16.3) U/L and (57.2±9.9) U/L, respectively (t=7.864, P＜0. 01).The glycocholic acid levels were (444.22±476.74) mg/L and (556.88±733.05) mg/L, respectively (t=0.938, P＜0.05). The Ⅳ-collagen(Ⅳ-C) levels were (45.13±8.25) ng/mL and (47.88±4.51) ng/mL, respectively (t= 2.129, P＜0.05). The riacylglycerol levels were (1.57±0.65)mmol/L and (2.51±1.29) mmol/L, respectively (t=4.737, P＜0.01). The blood uric acid levels were (298.5±48.2) mmol/L and (495.1±89.4) mmol/L, respectively (t= 14.092, P＜0.01).Conclusions The efavirenz-based therapy is efficacious in HIV/HCV co-infected patients, but it could cause liver injury and metabolic disorder.
